ArticleInternational journal of cancer2012
Survival outcomes in endometrial cancer patients are associated with CXCL12 and estrogen receptor expression.
Article in International journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2015Pooled it
- Identifying low-risk breast cancer patients for axillary biopsy exemption: a multimodal preoperative predictive model.European journal of medical research · 2025Article
- Increased PRP19 in Hepatocyte Impedes B Cell Function to Promote Hepatocarcinogenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Identification of immune-related gene signature for predicting prognosis in uterine corpus endometrial carcinoma.Scientific reports · 2023Article
- The Co-Expression of Estrogen Receptors ERα, ERβ, and GPER in Endometrial Cancer.International journal of molecular sciences · 2023Article
- The Exploration of Chemokines Importance in the Pathogenesis and Development of Endometrial Cancer.Molecules (Basel, Switzerland) · 2022Review
- miRNAs in the Expression Regulation of Dopamine-Related Genes and Proteins in Endometrial Cancer.Journal of clinical medicine · 2021Article
- Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma.Cancer cell international · 2020Article
- Identification of six candidate genes for endometrial carcinoma by bioinformatics analysis.World journal of surgical oncology · 2020Article
- Estradiol-regulated innate antiviral responses of human endometrial stromal fibroblasts.American journal of reproductive immunology (New York, N.Y. : 1989) · 2018Article
- Silencing of CXCR4 and CXCR7 expression by RNA interference suppresses human endometrial carcinoma growthAmerican journal of translational research · 2017Article
- Inhibition of CXCR4 and CXCR7 for reduction of cell proliferation and invasion in human endometrial cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis.Journal of hematology & oncology · 2016Article
- Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF.Oncotarget · 2015Article
- Construction of a CXCL12-KDEL fusion gene to inhibit head and neck squamous cell carcinoma metastasis by intracellular sequestration of CXCR4.BioMed research international · 2015Article
- Stromal derived factor-1 (SDF-1) and its receptors CXCR4 and CXCR7 in endometrial cancer patients.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
CXCL12 is a chemotactic cytokine that has pro-metastatic functions in several malignancies through interactions with its receptor, CXCR4. CXCL12 is an estrogen-regulated gene, and notably, estrogen is a major risk factor for endometrial cancer (EC) development. As few studies examine concurrent CXCL12, CXCR4, and estrogen receptor (ER) expression in EC patients, we examined this pathway in 199 EC patients with data from the University of Pittsburgh Medical Center Cancer Registry. Immunohistochemistry (IHC) was used to detect CXCR4, CXCL12 and ER protein expression. As CXCR4 expression was positive in all cases, this investigation focused on associations between CXCL12 and ER expression, clinicopathologic factors and survival outcomes using chi-square tests, Kaplan-Meier graphs, and log-rank tests. CXCL12 expression was negative in 63 cases (32%) and positive in 136 cases (68%). Negative CXCL12 expression was borderline significantly associated with metastasis (χ(2) p = 0.07). ER expression was negative in 75 cases (38%) and positive in 124 cases (62%). Positive ER expression was significantly associated with low grade and early stage tumors (χ(2) p < 0.001). CXCL12 and ER were not significantly associated (χ(2) p = 0.11). Positive CXCL12 expression was associated with longer overall survival (OS) (log-rank p = 0.006) and longer recurrence-free survival (RFS) (log-rank p = 0.01) in ER negative patients, but not in ER positive patients. We identified a unique molecular signature associated with better OS and RFS in EC patients. In addition to pathological characteristics of the tumor, expression of CXCL12 and ER may be clinically useful for assigning adjuvant treatment to EC cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.